drugset / Trial / NCT00659503

Study Using the Environmental Exposure Unit (EEU) to Assess the Onset of Action of Ciclesonide, Applied as a Nasal Spray in the Treatment of Seasonal Allergic Rhinitis (BY9010/M1-407)

NCT00659503

Phase 3 Completed 420 enrolled AstraZeneca
RandomizedParallel-groupDouble-blindTreatment

Summary

The primary objective of this placebo-controlled EEU study is to determine the time to onset of action of ciclesonide, applied as a nasal spray (200 mg, once daily) in patients with SAR.

Timeline

Start
2005-02
Primary completion
2005-04
Completion
2005-11

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ciclesonide Other / unclassified 200 ug Intranasal